Shiga Toxin Activates Complement and Binds Factor H: Evidence for an Active Role of Complement in Hemolytic Uremic Syndrome1
暂无分享,去创建一个
H. Karch | M. Dierich | Simon J. Clark | R. Würzner | M. Joannidis | H. Stoiber | L. Zimmerhackl | D. Orth | K. Grif | J. Brockmeyer | A. Naim | A. Khan | A. Day | Sonja Fidanzi
[1] H. Cook,et al. Shiga toxin‐2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H‐deficient mice , 2009, Clinical and experimental immunology.
[2] H. Jarva,et al. Complement factor H allotype 402H is associated with increased C3b opsonization and phagocytosis of Streptococcus pyogenes , 2008 .
[3] G. Remuzzi,et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. , 2008, Journal of the American Society of Nephrology : JASN.
[4] A. Friedrich,et al. New Immuno-PCR Assay for Detection of Low Concentrations of Shiga Toxin 2 and Its Variants , 2008, Journal of Clinical Microbiology.
[5] R. Würzner,et al. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans , 2008, Expert review of anti-infective therapy.
[6] M. Dierich,et al. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. , 2007, Diagnostic microbiology and infectious disease.
[7] D. Uhrín,et al. Structural basis for complement factor H–linked age-related macular degeneration , 2007, The Journal of experimental medicine.
[8] John D Lambris,et al. The role of complement in inflammatory diseases from behind the scenes into the spotlight. , 2007, The American journal of pathology.
[9] A. Blom,et al. The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells* , 2007, Journal of Biological Chemistry.
[10] John D Lambris,et al. The C-terminus of complement factor H is essential for host cell protection. , 2007, Molecular immunology.
[11] R. Würzner,et al. What makes an enterohemorrhagic Escherichia coli? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Victoria A. Higman,et al. His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form* , 2006, Journal of Biological Chemistry.
[13] P. Jennings,et al. Mechanisms of Neutrophil Transmigration Across Renal Proximal Tubular HK-2 Cells , 2006, Cellular Physiology and Biochemistry.
[14] C. Sabin,et al. Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. , 2006, The Journal of infectious diseases.
[15] H. Karch,et al. Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome , 2006, Seminars in thrombosis and hemostasis.
[16] H. Karch,et al. Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.
[17] R. T. Smith,et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] F. Proulx,et al. Mannan‐binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome , 2003, Clinical and experimental immunology.
[19] S. Ranganathan,et al. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. , 2000, European Journal of Immunology.
[20] D. Pérez-Caballero,et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. , 2002, American journal of human genetics.
[21] P. Ray,et al. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome , 2001, Pediatric Nephrology.
[22] V. V. van Hinsbergh,et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. , 2000, Blood.
[23] J. Samuel,et al. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. , 1999, The Journal of infectious diseases.
[24] L. Monnens,et al. Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels in Urine and Serum of Patents with Hemolytic Uremic Syndrome , 1998, Pediatric Research.
[25] T. Horiuchi,et al. C5a Induces Tissue Factor Activity on Endothelial Cells , 1997, Thrombosis and Haemostasis.
[26] P. Lachmann,et al. Molecular basis of the complement C7 M/N polymorphism. A neutral amino acid substitution outside the epitope of the allospecific monoclonal antibody WU 4-15. , 1995, Journal of immunology.
[27] J. Samuel,et al. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages , 1994, Infection and immunity.
[28] P. Lachmann,et al. Complement-mediated adipocyte lysis by nephritic factor sera , 1993, The Journal of experimental medicine.
[29] G. Fick,et al. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. , 1992, Nephron.
[30] R. Cotran,et al. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. , 1990, Journal of the American Society of Nephrology : JASN.
[31] T. Barrett,et al. Evidence for participation of the macrophage in Shiga-like toxin II-induced lethality in mice. , 1990, Microbial pathogenesis.
[32] P. Lambert,et al. The complement system in hemolytic-uremic syndrome in childhood. , 1980, Clinical nephrology.